Wild Animals Not Pets – The Case for an EU Positive List
This video captures highlights from the event: Wild Animals Not Pets – The Case for an EU Positive List.
A gathering of policymakers, experts, and animal welfare advocates at the European Parliament to discuss the trade in wild animals and its implications for welfare, health, and biodiversity | 22 Jul 2025 | 12:00 | 1 min. read | video
This video captures highlights from the event: Wild Animals Not Pets – The Case for an EU Positive List.
A gathering of policymakers, experts, and animal welfare advocates at the European Parliament to discuss the trade in wild animals and its implications for welfare, health, and biodiversity. Speakers reflected on the importance of: Establishing an EU-wide positive list of species permitted as pets
Addressing the risks wild animal trade poses to animal welfare, public health, and biodiversity
Tackling fragmented national rules and the need for harmonised EU legislation
Strengthening EU animal welfare frameworks to better protect wild species At a time when animal welfare and biodiversity face increasing pressures, these insights point to the need for coherent, science-based policies that safeguard both animals and society. Euractiv is part of the Trust Project More from this section
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euractiv
18 hours ago
- Euractiv
Delay in Bulgaria's free antibiotics plan for children sparks resistance fears
Bulgaria has failed to fulfil its promise to provide a large number of free antibiotics for children up to the age of seven, with the state managing to contract only a single manufacturer for one medicinal product. Widespread use of a single medicine could increase antibiotic resistance, experts warn. Earlier this year, the National Healthcare Fund (NHF) allocated a budget to make medicines for 117 diagnoses of acute infectious diseases available at no cost to the youngest children from July 1. Despite assurances from leading MPs in the ruling coalition, the state fund failed to secure the medicines at the start of July, as pharmaceutical companies showed little interest in signing supply contracts for these products. According to paediatricians, GPs, hospital doctors, and pharmacists Euractiv has spoken to, by the end of July, only a generic form of azithromycin, in two doses, produced by a Bulgarian pharmaceutical company, was being reimbursed. 'The state's decision to offer free antibiotics was populist,' commented Dr Margarita Sharkova, a paediatrician and general practitioner with one of the largest practices in the capital Sofia, speaking to Euractiv. Structural issues repel industry 'The antibiotic currently available for free is not even a first-line treatment. But even if more antibiotics are eventually made available free of charge, the money could have been spent far more wisely, for example, on prevention. Free varicella vaccines could have been provided instead,' Sharkova said. According to her, pharmaceutical companies' reluctance to sign contracts with the state is entirely understandable, as the state simply does not pay well. 'We all know how the Health Fund pays for medicines,' Dr Sharkova noted. Previous Euractiv in-depth reporting on the issue has highlighted the substantial discounts Bulgaria demands from pharmaceutical companies in a bid to cut costs. Private firms find it much more advantageous to sell their products through the pharmacy network rather than sign contracts with the state, which involves navigating excessive bureaucracy to supply cheaper antibiotics. Agitating AMR In informal conversations, hospital doctors expressed concern to Euractiv that offering a limited number of antibiotics without charge could lead to an increase in antimicrobial resistance (AMR). The fear is that in poorer and smaller Bulgarian towns, as well as in deprived Roma neighbourhoods in larger cities, economic necessity will lead to widespread use of the only available free option. In response to a Euractiv question, Dr Sharkova also acknowledged this possibility. At the start of the year, the Bulgarian parliament allocated an initial sum of €5 million to the NHF to launch the programme. It only became clear in July that the mechanism would not start on time, and that the state would cover only the cheapest available product in each drug category. This means that parents will still have to pay out of pocket for newer generations of antibiotics. In early July, Health Minister Sylvi Kirilov announced that he had done everything possible to help accelerate the procedure for approving publicly funded medicines. Similarly, Sofia has also failed to use the funds allocated in 2025 for biomarker diagnostics in cancer care, as it has not been able to approve the necessary procedures for utilising the financing. The Health Ministry stated that all marketing authorisation holders had been invited to submit applications for the inclusion of medicinal products in the Positive Drug List for reimbursement. [Edited by Vasiliki Angouridi]
Euractiv
18 hours ago
- Euractiv
Last-resort antibiotic excluded from Belgian system, testing EU pharma reforms
A critical antibiotic designed to treat infections caused by multidrug-resistant bacteria will remain unavailable through Belgium's reimbursement system after negotiations between the government and the manufacturer failed. The problem goes far beyond Belgium. The inability to secure access to cefiderocol reflects a broader European market failure in valuing and funding last-resort antibiotics. 'The fight against antimicrobial resistance (AMR) is a spearhead of your policy and was a priority during the recent Belgian EU presidency,' MP Irina De Knop (Open VLD) told Health Minister Frank Vandenbroucke in the Belgian Parliament on 15 July, addressing the issue. 'The challenge lies not only in preventing resistance but also in ensuring access to scarce, new antibiotics that serve as last-resort treatments.' First-in-class antibiotic Cefiderocol is not a generic antibiotic. It is a first-in-class, patented siderophore cephalosporin developed by Shionogi, approved in the EU in 2020 under the name Fetcroja®. Specifically engineered to treat carbapenem-resistant Gram-negative bacteria such as Acinetobacter baumannii and Pseudomonas aeruginosa , it penetrates bacterial defences by hijacking iron uptake pathways. Its novel mechanism and limited target population make it difficult to assess using traditional volume-based pricing and reimbursement models designed for high-volume generics. Cefiderocol targets 'superbugs' identified by the World Health Organisation (WHO) as priority pathogens and is intended for an estimated 200 patients per year in Belgium, typically those with no remaining treatment options. 'Precisely because of this limited target group, it is hardly commercially viable,' said De Knop. 'The societal value of reserve antibiotics lies not in frequent use, but in their availability. This leads to a 'broken market' that threatens innovation and sustainable access.' Cost and safety criteria Minister Vandenbroucke confirmed that Belgium's reimbursement process for cefiderocol ended without a deal. 'We went far to reach an agreement, especially for those 55 patients,' he said. 'But apparently, even with far-reaching proposals, we could not meet the company's demands. The requested price is more than double that of the most expensive reimbursed late-line antibiotic.' Citing limited clinical evidence and safety concerns from one comparative trial, the minister explained that the antibiotic is classified as a true last-line option and must be kept outside the hospital's regular reimbursement system due to its high cost. 'In the absence of strict prescription controls, there's a risk it would be used too broadly, potentially accelerating resistance to this last-resort treatment,' he warned. While Belgium is monitoring EU-level initiatives, including push and pull incentives and alternative financing mechanisms, the minister acknowledged: 'There are currently no concrete plans to introduce a subscription financing model like in the United Kingdom.' Company calls for pan-European rethink The product's manufacturer, Shionogi, told Euractiv that Belgium's decision reflects a systemic issue across Europe. 'Reserve antibiotics play a vital role in treating infections caused by multidrug-resistant (MDR) pathogens, often when no other options remain,' the company said. 'Although used in very small patient populations, these antibiotics offer immense public health value, yet current reimbursement systems are not designed for low-volume, high-importance medicines.' The company cited remarks made by Minister Vandenbroucke during an AMR conference held under the Belgian Presidency of the Council in June 2024: 'Look at antibiotics: they should not be used too much. However, some of them have to be ready as soon as you need them. For that, you need a different kind of financing, almost like a subscription to a streaming service.' 'These initiatives, including the 'streaming service' model referenced by Minister Vandenbroucke, are aligned with G7 health priorities and show how sustainable innovation and access can go hand in hand,' the company said. Shionogi confirmed participation in delinked funding pilots: 'Yes. Shionogi is actively participating in the UK's NHS AMR Subscription Model, which pays for antibiotics based on their value to the health system, not the volume used. We were also involved in Sweden's national pilot and are engaged in discussions with HERA on similar approaches.' 'We recognise that European countries have unique needs. In Belgium, as across Europe, we're always open to solutions that deliver timely access for patients, reward responsible use, and make continued innovation in antibiotics possible,' the company's CEO Huw Tippett told Euractiv. A test case for the EU's Pharmaceutical Package Despite Belgium's efforts to strike a deal, MP De Knop warned that the lack of reimbursement leaves patients at risk. 'The result remains that this antibiotic, which is particularly important for a small group of people, is currently not reimbursed,' she said. 'You also did not present an immediate solution,' pointing to the minister. Belgium plans to introduce 'early and fast access' procedures by 2026, but currently lacks a dedicated funding stream for reserve antimicrobials. With no viable market and limited public procurement tools, cefiderocol has become a test case for Europe's broader pharmaceutical policy agenda. Antibiotic incentives are central to the EU's Pharmaceutical Package, currently under negotiation. The European Commission has proposed transferable exclusivity vouchers and pull incentives to stimulate antimicrobial innovation, though these remain politically contentious. Under the Belgian Council Presidency in June 2024, EU health ministers adopted Council conclusions calling on the European Commission and Member States to 'explore alternative reimbursement models, such as subscription-based schemes,' and to strengthen 'EU-level coordination to ensure sustainable access to critical antimicrobials.' These conclusions were part of the strategy paper 'The Future of the European Health Union: a Europe that cares, prepares and protects.' While often associated with generic shortages, the proposed Critical Medicines Act also introduces tools such as joint procurement, strategic stockpiling, and EU-wide demand coordination, all of which could be applicable to patented, last-resort antibiotics like cefiderocol. [Edited by Vasiliki Angouridi]
Euractiv
3 days ago
- Euractiv
Mounting pressure on Sweden over Gaza medevac refusals
The Swedish government is facing increased pressure to admit wounded Palestinian patients, having consistently refused to assist with medical evacuation from the Gaza Strip. The centre-right coalition government, composed of Moderates, Liberals, and Christian Democrats, is arguing that Sweden already supports Egyptian healthcare with medical equipment and also supports UN bodies, such as UNICEF and UNFPA, by providing healthcare and humanitarian support on the ground. "The government does not rule out, as other countries do, accepting patients for care in Sweden as a complement to on-site assistance. In each case, consideration must be given to the circumstances, what solutions will provide the fastest help to those in need, and also how we can best help as many people as possible. In the current context, it is crucial to ensure that people receive immediate help where they are," Acko Ankarberg Johansson, the Christian Democrat Health Minister, told Euractiv. Agency on standby Magdalena Tham Lindell, head of humanitarian operations at the Swedish Civil Contingencies Agency (MSB), told Euractiv that the agency has so far had to turn down 37 requests from the EU Civil Protection Mechanism for the medical evacuation of trauma patients from Gaza since the conflict between Hamas and Israel began. "We do not have any mission from the Swedish government to carry out such a task," she added. However, Tham Lindell also said that the Civil Contingencies Agency is ready to carry out medical transport of patients from Gaza to Sweden. "Yes, we are well prepared to do this if we receive such a mission," she said. As early as 2023, the acting EU Commissioners, Stella Kyriakides and Janez Lenarčič, urged member states to provide care to patients from Gaza. The UN and the WHO have also been calling for assistance and support. Pressure on Sweden Despite an EU-wide slow reaction, 14 EU countries, including Italy, Romania, and Spain, are currently assisting with medical evacuations from Gaza, according to the EU mechanism. With the situation deteriorating into a worst-case scenario involving widespread hospital destruction, starvation and the killing of civilians by the Israeli side, calls for the evacuation of wounded children and adults have grown louder and more frequent in Sweden. Stakeholders, including the Swedish Association of Health Professionals (the union representing nurses and midwives), doctors, hospitals, and private care providers, have requested that ministers revise their position. The Hospital Doctors Association has recently reiterated its request to allow Gaza patients admission into Sweden in an open letter to the government. "We are dismayed that despite the readiness of healthcare providers, the Swedish government is refusing to accept patients from Gaza," the association's board wrote. Parliamentary pressure Daniel Helldén, one of the Swedish Green Party's two spokespersons, also formally asked Ulf Kristersson, the Swedish Prime Minister, what would make the government change its mind on the issue. "We have individual regions, hospitals and doctors who want to help. Many other countries have helped. Doctors who have been on the ground say that their resources are not enough while the killing continues. I can't for the life of me understand why the government is saying no to this," he told Dagens Nyheter. Fredrik Lundh Sammeli, Health Spokesperson and a Parliamentarian for the Social Democrats, the Swedish main opposition party, recently asked on Facebook: "How long will the government stand by while children die?" If the Swedish Parliament had been open, he wrote, he would already have called the Minister for Health to the Social Affairs Committee to answer: "Why does Sweden refuse to accept injured children from Gaza, when other European countries do?" Passive stance Lundh Sammeli also told Euractiv that the party considers that the government has taken a far too passive position on the Gaza issue. "This is sad. Sweden should be committed to assisting people in need during humanitarian disasters and conflicts. We have received seriously injured people from Ukraine and should have the same attitude to the Gaza war as part of the coordinated European effort." He insisted that on-the-spot help and transporting seriously injured people to Swedish hospitals are not mutually exclusive. Sweden has so far received and treated 237 patients from Ukraine since the Russian full-scale invasion in 2022, Johan Köhler, Programme Manager at the National and Civil Protection Operations Section of the MSB, told Euractiv. According to the BBC and the Sunday Times, the UK government now plans to evacuate up to 300 seriously ill or wounded children from Gaza. The plan could be set into action within weeks. A private initiative has already brought Palestinian children from Gaza to the UK. [Edited by Vasiliki Angouridi]
